Previous 10 | Next 10 |
Montrouge, France, August 1, 2022 DBV Technologies Reports Second Quarter 2022 Financial Results DBV closes Q2 with a cash balance of $248M following recent ATM and PIPE offerings DBV continues to practice budget discipline measures; cash used in operating ...
Monthly information regarding the total number of voting rights and total number of shares of the Company as of June 30, 2022 (Article 223-16 of the General Regulations of the Autorité des Marchés Financiers ) Market : NYSE Euronext Paris ...
DBV Technologies is a French company traded on Nasdaq which is developing treatments for food allergies. Their technology is a patch that delivers a very small daily dose of the allergen to desensitize the patient. The company previously received a CRL due to issues with the adhes...
Kohl's ( KSS ) -19% after ending strategic review, warning on soft Q2 sales ; on terminating deal talks with Franchise Group . Borr Drilling ( BORR ) -15% gets more time from lenders on refinancing talks . Revelation Biosciences ( REVB ) -12% ...
Baker Brothers’ 13F portfolio value decreased from $20.55B to $17.40B this quarter. Horizon Therapeutics was increased while decreasing Legend Biotech. The top three positions are Seagen, Incyte Corporation, and BeiGene, and they add up to almost 68% of the portfolio. ...
The biotech industry is volatile. It's not that rare to see shares of relatively small drugmakers skyrocket on positive clinical or regulatory news. Case in point: Axsome Therapeutics (NASDAQ: AXSM) and DBV Technologies (NASDAQ: DBVT) -- two small-cap biotechs -- recently sa...
Montrouge, France, June 28, 2022 DBV Technologies to Participate in Upcoming EAACI 2022 Congress DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced upcoming ...
Montrouge, France, June 16, 2022 DBV Technologies to Present at the JMP Securities Life Sciences Conference in New York DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, to...
Redbox Entertainment (RDBX) -21%. Hillstream BioPharma (HILS) -13%. DBV Technologies (DBVT) -11%. Day One Biopharmaceuticals (DAWN) -8% on $125M share offering. AeroClean Technologies (AERC) -8%. MicroStrategy (MSTR) -7% Bitcoin and ether deepen their slump, pulling MicroS...
MicroStrategy (MSTR) -25% as crypto market cap sinks below $1T. Astra Space (ASTR) -25% after latest mission failure. Qutoutiao (QTT) -21%. Marathon Digital Holdings (MARA) -17% as crypto market cap sinks below $1T. Bitfarms (BITF) -17% as cry...
News, Short Squeeze, Breakout and More Instantly...
DBV Technologies S.A. Company Name:
DBVT Stock Symbol:
NASDAQ Market:
DBV Technologies S.A. Website:
Information regarding the total number of voting rights and total number of shares of the Company as of July 31, 2024 (Article 223-16 of the General Regulations of the Autorité des Marchés Financiers ) Market : NYSE Euronext Paris ISIN Code: FR 0010417345 ...
Châtillon, France, July 30, 2024 DBV Technologies Announces Filing of 2024 Half-Year Report ― Conditions for Accessing or Consulting the Report DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutic...
Châtillon, France, July 30, 2024 DBV Technologies Provides Updates on the Viaskin Peanut Program in Children and Toddlers and Reports Second Quarter and Half-Year 2024 Financial Results VITESSE enrollment in peanut allergic 4-7-year-olds is on-track and recruitment is expecte...